Lilly's REYVOW is the first and only new type of acute migraine treatment that is now available for prescription in the United States

Lilly announced today that REYVOW (Iasmiditan) C-V 50 mg and 100 mg tablets for acute treatment of adult patients with or without preeclampsia can now be prescribed and available at pharmacies in the next few daysREYVOW is different from other acute treatments for migrainesREYVOW, as a new type of acute treatment for migraines, is the first and only 5-HT 1F receptor agonist approved by theFDA, which acts on the central and peripheralREYVOW is offered to patients at doses of 50 mg, 100 mg and 200 mg, respectively, providing doctors and other prescribers with flexible methods of administrationin two randomized, double-blind, placebo-controlledclinicaltrials (SAMURAI and SPARTAN), REYVOW was shown to be effective in treating migraines in 4,439 patients who took doses of 50 mg, 100 mg or 200 mg, respectivelypain relief, defined as reducing moderate or severe headaches to pain-free within two hours, with no self-identifying MBS (fear of light, fear, or nausea), and is set to the primary and secondary end of the effectIn twoclinicalstudies and three doses, REYVOW eliminated migraines completely in 28-39% of patients within two hours, compared with 15% and 21% in the placebo groupIn two hours, 41-49% of patients were given out of MBS, compared with 30% and 33% in the placebo group